Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept OLE in IgAN
NCT07807995Phase 3Enrolling by invitation
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of povetacicept in immunoglobulin A nephropathy (IgAN), sponsored by Vertex Pharmaceuticals. Started Sep 2026; status: enrolling by invitation.
02
Drugs
povetacicept
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07807995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807995.